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Abstract
Objectives To determine the long term clinical effectiveness of
laparoscopic fundoplication as an alternative to drug treatment for chronic
gastro-oesophageal reflux disease (GORD).
Design Five year follow-up of multicentre, pragmatic randomised trial
(with parallel non-randomised preference groups).
Setting Initial recruitment in 21 UK hospitals.
Participants Responders to annual questionnaires among 810 original
participants. At entry, all had had GORD for >12 months.
Intervention The surgeon chose the type of fundoplication. Medical
therapy was reviewed and optimised by a specialist. Subsequent
management was at the discretion of the clinician responsible for care,
usually in primary care.
Main outcomemeasures Primary outcome measure was self reported
quality of life score on disease-specific REFLUX questionnaire. Other
measures were health status (with SF-36 and EuroQol EQ-5D
questionnaires), use of antireflux medication, and complications.
Results By five years, 63% (112/178) of patients randomised to surgery
and 13% (24/179) of those randomised to medical management had
received a fundoplication (plus 85% (222/261) and 3% (6/192) of those
who expressed a preference for surgery and for medical management).
Among responders at 5 years, 44% (56/127) of those randomised to
surgery were taking antireflux medication versus 82% (98/119) of those
randomised to medical management. Differences in the REFLUX score
significantly favoured the randomised surgery group (mean difference
8.5 (95% CI 3.9 to 13.1), P<0.001, at five years). SF-36 and EQ-5D
scores also favoured surgery, but were not statistically significant at five
years. After fundoplication, 3% (12/364) had surgical treatment for a
complication and 4% (16) had subsequent reflux-related
operations—most often revision of the wrap. Long term rates of
dysphagia, flatulence, and inability to vomit were similar in the two
randomised groups.
Conclusions After five years, laparoscopic fundoplication continued to
provide better relief of GORD symptoms than medical management.
Adverse effects of surgery were uncommon and generally observed
soon after surgery. A small proportion had re-operations. There was no
evidence of long term adverse symptoms caused by surgery.
Trial registration Current Controlled Trials ISRCTN15517081.
Introduction
Trials of laparoscopic fundoplication surgery1-8 provide
promising evidence of better short term symptomatic relief than
continued medical management among people who would
otherwise require continuous or intermittent medication for
reasonable control of gastro-oesophageal reflux disease (GORD).
Uncertainty remains about whether benefits are sustained and
outweigh risks, subsequent drug use, and unwanted symptoms
such as dysphagia and flatulence.7 We therefore undertook five
year follow-up within a multicentre, UK based, randomised
controlled trial, the REFLUX trial.
Methods
Design and participants
The studywas approved by the ScotlandAMulticentre Research
Ethics Committee (MREC/00/0/30). The design and one year
results have been reported previously,1 2 9 and a detailed report
of the follow-up is also available.10 The trial was pragmatic11
comparing a policy of laparoscopic fundoplication with a policy
of optimised continued medical management. Patients were
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eligible if they hadmore than 12months’ maintenance treatment
with a proton pump inhibitor (or alternative) for reasonable
control of GORD symptoms, they had evidence of GORD
(endoscopic or 24 hour pH monitoring, or both), they were
suitable for either policy, and the recruiting doctor was uncertain
which management policy to follow.
Clinical management
Participating clinical centres had partnerships between surgeons
and gastroenterologists who shared the secondary care of
patients with GORD. They assessed eligibility and, working
with research nurses, informed participants about the trial.
Randomisation was organised centrally and computer generated.
Participants who declined to take part in the randomised trial
because of a strong preference either for remaining on medical
management or for undergoing surgery were then given the
opportunity to join one of two non-randomised preference
arms.12 All participants gave informed consent.
For all participants in either the randomised or preference
surgical groups, surgery could be deferred or declined after trial
entry, by either the patient or the surgeon. A lead surgeon who
had performed at least 50 laparoscopic fundoplication operations
(or a surgeon working under supervision) undertook the surgery.
The type of fundoplication was decided by the surgeon. We
considered the different fundoplication techniques as a single
policy. Those allocated to medical treatment had their treatment
reviewed and adjusted as judged best by a local
gastroenterologist.13 The medical protocol included the option
of surgery if a clear indication developed after randomisation.
In all groups, subsequent management was decided by the
clinician responsible for care; most later care was in general
practice.
Outcome measures
The primary outcome was the score from the REFLUX
questionnaire,14 a validated measure of health related quality of
life for patients with GORD that incorporates assessment of
reflux related and other gastrointestinal symptoms and the side
effects and complications of both treatments (scores ranged
from 0 to 100, with the higher the score the better the patient
felt). Other measures were health status (SF-3615 and EuroQol
EQ-5D16), use of antireflux drugs, reflux related surgery and its
complications, and individual symptoms. Participants were
followed up by postal questionnaire (copies available on request)
at equivalent to 3 and 12months after surgery, and subsequently
annually for five years.
Sample size and statistical analysis
The original sample size of 176 per group was chosen to give
80% power (α=0.05) to detect a difference of 0.3 of one standard
deviation (equivalent to 7 points) in the REFLUX questionnaire
score. Secure randomisation was organised centrally using a
computer generated sequence, stratified by clinical site, with
balance in age, sex, and body mass index secured by
minimisation.2 There was no subsequent blinding. Figure 1⇓
summarises the stages of the study in a CONSORT diagram.
Primary statistical analysis in the randomised comparison was
by intention to treat. The REFLUX questionnaire score, SF-36,
EQ-5D, and antireflux drug use were analysed using general
linear models. The analyses were adjusted for the minimisation
covariates; in addition, the randomised comparisons were also
adjusted for baseline REFLUX questionnaire scores and for
baseline by treatment interaction. Sensitivity to assumptions
about missing values was explored using a repeated measures
analysis.17 Secondary “adjusted treatment received” analyses 18
were based on actual treatment in the first year. These are similar
to per protocol analyses but are less prone to bias; they give a
measure of efficacy of surgery when compared with medical
management.
Results
Recruitment took place in 21 UK centres between March 2001
and June 2004: 357 patients recruited to the randomised
comparison (178 to surgery and 179 to medical management)
and 453 recruited to non-randomised preference groups (261
for surgery and 192 for medical management).
Description of trial groups
As described previously,1 2 the randomised groups were balanced
at trial entry. Follow-up rates decreased over time (318/357
(89%) at 1 year to 246/357 (69%) at 5 years). Four randomised
participants are known to have died by five years—none related
to trial participation. Respondents at five years tended to have
been older at entry, to have been prescribed medication for a
shorter time before recruitment, and to have had higher baseline
quality of life scores. However, other than in baseline bodymass
index (table 1⇓), respondents at five years were similar in the
two randomised groups. The baseline characteristics of the
randomised groups lay between those of the preference groups:
members of the group who expressed a preference for surgery
were younger, had been prescribed drugs for GORD for longer,
and had lower baseline REFLUX scores; participants who
preferred medical treatment were older, more likely to be
women, had been prescribed medication for a shorter time, and
had higher baseline REFLUX scores.
Clinical management
By five years, 112 (62.9%) of the 178 patients randomised to
surgery had received fundoplication (table 2⇓)—53 (47.3%)
with a total wrap and 59 (52.7%) with a partial wrap. Surgery
was also performed for 24 (13.4%) of the 179 patients
randomised to medical management—10 in the first year and
14 in years 2–5; post hoc analyses showed that these 24 had
significantly lower baseline REFLUX questionnaire scores than
those randomised to medical management who did not have
surgery. Of the total of 364 patients who had fundoplication
(randomised and preference groups), 16 (4.4%) had a subsequent
reflux related reoperation—mainly a reconstruction of the same
wrap or conversion to another type of wrap—and 12 (3.3%)
had a late complication (table 2⇓).
Figure 2⇓ shows the use of antireflux drugs in the four
participant groups based on intention to treat. This applied to
37.7% (58/178) of those randomised to surgery versus 90.2%
(148/179) of those randomised to medical management at one
year follow-up and to 44.1% (56/127) versus 82.4% (98/119)
at five years. The equivalent rates among those randomised to
surgery who had surgery in the first year were 9.6% (10/104)
at one year rising to 26.7% (24/90) at five years. The most
commonly prescribed proton pump inhibitors were omeprazole,
lansoprazole, and esomeprazole.
Health status and symptoms
The REFLUX questionnaire mean scores at all follow-up time
points were highest in the groups randomised to surgery or who
preferred surgery (fig 3⇓). The differences between the surgical
and medical groups narrowed over time, principally because
the scores for the group randomised to medical treatment
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improved over the first three years. However, there were still
clear differences between the randomised groups at five years:
mean difference 8.5 (95% confidence interval 3.9 to 13.1,
P<0.001) for intention to treat, 11.5 (4.2 to 18.7, P=0.002)
adjusted for treatment received; and 8.1 (4.4 to 11.7) for repeated
measures analysis.
Heartburn, regurgitation, and belching were reported less
frequently in the group randomised to surgery than among those
randomised to medication, with no significant differences in
‘difficulty swallowing’, ‘wind from the bowel’ and ‘wanting to
be sick but being unable’ (table 3⇓).
SF-36 scores favoured the surgical group in all domains at all
time points. Differences decreased over time, and this decrease
is reflected in most P values being <0.05 up to three years’
follow-up, whereas at five years only the norm-based general
health and role emotional domains had P values <0.05 (table
4⇓). Mean EQ-5D scores showed a similar pattern—differences
all favouring the surgical group but tending to narrow so that
scores at years 2 and 3 were significantly different but not at
later time points (table 4).
Preference groups
The preference surgery group had a markedly lower mean
REFLUX score at baseline than the preference medical group
(55.8 v 77.5, equivalent to 1 SD). Despite this, all subsequent
scores favoured the preference surgery group (fig 3⇓). Other
quality of life scores showed a similar pattern.
Discussion
Principal findings
After five years, a policy of laparoscopic fundoplication among
patients for whom reasonable control of GORD symptoms
required long term medication and for whom both surgery and
medical management were suitable continued to provide better
relief of GORD symptoms with associated improved health
related quality of life. Despite some narrowing over time, the
difference in the primary outcome measure remained highly
significant at five years. There was reassuringly little evidence
of new chronic symptoms caused by surgery. Reoperations and
complications of surgery occurred early after surgery and were
uncommon.
Strengths and weaknesses of study
The trial design was pragmatic, aiming to make clinical
management similar to normal NHS care, and so the results
should be generalisable to standard care. The trial compared
two policies for managing GORD (intention to treat analyses)
rather than directly comparing surgery with antireflux
medication. The first policy was earlier surgery for eligible
patients, when deemed appropriate and acceptable, with the
option to take medication if considered helpful. The second
policy was continued, initially optimised, medical management,
with “delayed” surgery in selected cases when considered
indicated.
Recruiting patients for randomisation to suchmarkedly differing
managements as surgery and medical treatment is challenging.
Patients who agree to be randomised have to be uncertain
between the two approaches, and hence it should be expected
that they sometimes change their minds once they discuss and
reflect on the implications of their allocation. These
circumstances are largely responsible for the apparently low
rate of surgery among those randomly allocated surgery
(112/178 (63%), table 1⇓) compared with those who expressed
a preference for surgery (218/261 (83%)). Among those
allocated surgery who did not have surgery in the first year, a
definite decision was later made not to have an operation for
47. For 25 of these, this was a clinical decision—most
commonly the surgeon deciding after randomisation that surgery
was not appropriate. Most of the others changed their minds
about having surgery for a variety of work or home related
reasons, because of worries about having surgery (after a fuller
discussion with the surgeon), because of a wish to avoid
unpleasant preoperative tests, or because their symptoms had
improved. In addition to these 47, a further 20 withdrew for
unknown reasons. There is no doubt that some of these
participants experienced long delays before formally being
offered surgery, and we believe that this was an important factor
in their eventual decision not to have surgery after all.
Recruitment and early treatment in the trial was conducted in
2001–4, when there was great pressure on surgical services in
the NHS, and long delays for elective surgery for non-life
threatening, benign conditions were common. (Average time
between trial entry and surgery in the trial was 8–9 months.)
Despite only 63% of those allocated surgery actually receiving
it, there were still clear differences in outcome between the
intention to treat groups. However, the analyses adjusted for
treatment received probably give better estimates of differential
effects in the randomised comparison in terms of efficacy. As
would be expected, these analyses gave larger estimates (11.5
v 8.5 for intention to treat), but they are more prone to bias.
The 69% response rate at five years is similar to the 67%
reported for the LOTUS clinical trial.7 The responders in the
randomised groups were generally similar in baseline
characteristics (table 1⇓). Although responders did show some
differences from non-responders, it is reassuring that the
repeated measures analysis that uses data from all follow-up
points gave broadly similar results to the intention to treat
analyses.
The 24 (13%) of the 179 participants randomised to medical
management who subsequently had surgery had significantly
lower baseline REFLUX questionnaire scores, which then
improved markedly. This group contributed to the narrowing
of differences over time between the two randomised groups
(fig 1⇓), and this is another reason why the analyses based on
intention to treat are likely to underestimate the effects of
surgery. Some participants did take medication intermittently.
The estimated longer term use of antireflux drugs (fig 2⇓) was
based on participants’ recall of the preceding two weeks and
may not fully reflect use over the entire year.
We anticipated that some eligible patients would have strong
preferences for their future management, especially when
clinical uncertainty was expressed. We gave these patients the
opportunity to participate in non-randomised preference groups.
These groups do aid the interpretation of the randomised trial
results in important ways: they provide added data on rare but
serious complications; they contextualise the randomised cohort
(which sits between the preference groups in terms of baseline
characteristics); they add further evidence of the effects of
surgery (the preference surgery group started with much lower
REFLUX questionnaire scores but had high scores after
surgery); and they provide better guides to real world
management in terms of surgical take up.
Comparison with other studies
Four randomised trials have compared laparoscopic
fundoplication with medical management of GORD.1-8 19 The
REFLUX trial had the most pragmatic design—for example,
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greater flexibility in the choice of surgical procedure. Also,
other trials incorporated regular specialist assessment of
antireflux medication and adjustment, whereas in REFLUX,
after initial review by a gastroenterologist, all subsequent
prescription was decided by the clinician responsible for normal
care, usually in primary care.
All four trials show significantly better relief of symptoms over
their length of follow-up. Limited data are available for generic
quality of life measures: while differences are less marked, they
are consistent with benefit from surgery. The trials are also
broadly consistent in showing small numbers of operations
needing to be converted to an open procedure, visceral injuries
associated with the procedure, postoperative problems, and
numbers requiring dilatation of the wrap. The REFLUX trial
suggests that 4.4% (16/364) have reoperations over five years,
broadly consistent with other trials.
The REFLUX trial’s main outcomes were patient reported,
providing “common currency” across trial policies independent
of clinical judgment. In contrast, the primary outcome in the
other large trial (LOTUS6 7) was “treatment failure” as judged
by cross over to the alternative treatment—all surgical patients
who developed a need for medication were classified into this
category whether or not their GORD symptoms were
satisfactorily controlled by that medication. A concern about
using patient reported outcomes is that completion of
questionnaires might be influenced by knowledge of
management received, but this possibility is likely to become
more remote as follow-up lengthens. Also, the randomised
component was limited to patients who were uncertain which
treatment to choose (those with strong views were enrolled into
the preference groups).
Where the REFLUX trial results differ from those of the other
trials, especially LOTUS,6 7 is the low prevalence of chronic
adverse symptoms associated with fundoplication. Although a
small number in the REFLUX trial did have a postoperative
dilatation procedure,1 2 later reports of difficulty swallowing,
flatulence, and wanting to vomit but being unable to do so were
similar in the two randomised groups (table 3⇓). These
differences between trials are important as they potentially alter
the balance between benefits and risks of surgery. A possible
explanation is the difference in fundoplication policies. In
REFLUX, the choice of operation was left to the surgeon, and
a high proportion of patients (53%) had a partial fundoplication.
In the LOTUS trial, a standardised protocol specified total
Nissen fundoplication.20 Partial fundoplication is associated
with a lower rate of postoperative side effects but may have a
higher rate of reoperation for recurrence of GORD.21
Meaning of the study
Five year follow-up has shown that laparoscopic fundoplication
for patients for whom reasonable control of GORD symptoms
requires long term medication, and for whom both surgery and
medical management are suitable, continued to provide better
relief of symptoms with associated improved quality of life.
The more troublesome the symptoms at baseline, the greater
the potential benefit from surgery. Decisions about surgery will
be informed by the balance between benefits and risks. In this
study, complications were rare and, unlike in other studies, there
was no evidence that surgery caused long term unwanted
symptoms such as difficulty swallowing.
Unanswered questions and future research
Patients and doctors making decisions about laparoscopic
fundoplication would be aided by clearer evidence about the
risks of long term morbidity and its associations with surgical
technique. People with GORD are usually managed in primary
care, and it is not clear currently how many such people might
seek fundoplication in light of the findings of this and other
trials.
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What is already known on this topic
Laparoscopic fundoplication surgery provides better short term symptomatic relief than continued medical management for people with
chronic gastro-oesophageal reflux disease (GORD)
Uncertainty remains about whether benefits are sustained and possible long term side effects such as dysphagia and flatulence
What this study adds
Five year follow-up of trial participants confirmed sustained benefits of surgery as an alternative to drug treatment for GORD
Adverse effects of surgery were uncommon and generally observed soon after surgery
Unlike in some other studies, unwanted long-term symptoms were not associated with surgery in this trial
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Tables
Table 1| Baseline characteristics of respondents at five year follow-up by randomisation to surgical or medical management for chronic
gastro-oesophageal reflux disease. Values are numbers (percentages) of participants unless stated otherwise
P value of difference*Medical (n=119 maximum)Surgical (n=127 maximum)Characteristic
0.1246.4 (11.6)
(n=119)
48.5 (9.3)
(n=127)
Mean (SD) age in years
Sex:
0.7976/119 (64)79/127 (62)Men
—43/119 (36)48/127 (38)Women
0.0127.7 (3.8)
(n=119)
29.0 (4.3)
(n=127)
Mean (SD) body mass index
0.1746.3 (60.1)
(n=117)
57.2 (63.4)
(n=124)
Mean (SD) months of antireflux medication before trial entry
Erosive oesophagitis:
0.3568/108 (63)63/111 (57)Yes
—39/108 (36)48/111 (43)No
H pylori infection status:
0.5210/92 (11)6/96 (6)Positive (treated)
—2/92 (2)1/96 (1)Positive (untreated)
—45/92 (49)55/96 (57)Negative
—34/92 (37)34/96 (35)Uncertain
Hiatus hernia:
0.9971/114 (62)73/117 (62)Yes
—43/114 (38)44/117 (38)No
Mean (SD) questionnaire scores:
0.3868.6 (24.0)
(n=110)
65.9 (23.7)
(n=121)
REFLUX†
0.510.755 (0.228)
(n=118)
0.736 (0.223)
(n=122)
EQ-5D‡
0.3046.1 (9.1)
(n=114)
44.8 (10.0)
(n=121)
SF-36 physical§
0.9846.5 (11.1)
(n=114)
46.6 (11.0)
(n=121)
SF-36 mental§
0.23109/118 (92)120/125 (96)Taking any proton pump inhibitor
0.11113/118 (96)124/125 (99)Taking any antireflux drug
*Using Student’s t test, χ2 test, or Fischer’s exact test as appropriate.
†REFLUX questionnaire a disease-specific measure of quality of life (score range 0–100).
‡EuroQol EQ-5D measure of health status.
§Short Form (36) Health Survey measure of health status.
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Table 2| Reflux related surgery and subsequent complications among participants with chronic gastro-oesophageal reflux disease who
were randomised to or selected surgical or medical management. Values are numbers (percentages) of participants
Total cohort
Participants with preferred treatmentParticipants randomised to treatment
Medical (n=192)Surgical (n=261)Medical (n=179)Surgical (n=178)
3 (1.6)218 (83.5)10 (5.6)111 (62.4)Fundoplication within 1 year of enrolment
6 (3.1)222 (85.1)24 (13.4)112 (62.9)Fundoplication at any time during 5 year follow-up
16 (4.4)2 (33.3)8* (4.5)1 (4.2)5 (4.5)Reflux related re-operation:
61212Reconstruction of same wrap
60402Conversion of type of wrap
21100Reversal of fundoplication
40301Repair of hiatus hernia only
12 (3.3)2 (33.3)8 (3.6)02 (1.8)Late postoperative complication†:
40301Oesophageal dilatation or stricture dilatation
30300Repair of incisional hernia
52¶2§01‡Other
*Two of the eight also had a third reflux related operation.
†Complication ≥1 month after operation.
‡Pain due to original wrap shifting.
§Admission for venous thromboembolism; pain from operation.
¶Hole between stomach and liver; bleed in stomach and/or bowel.
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Table 3| Frequency of related symptoms among participants at three and five year follow-up after randomisation to surgical or medical
management for chronic gastro-oesophageal reflux disease. Values are numbers (percentages) of participants
Year 5 follow-upYear 3 follow-upSymptom frequency
(No of times/week) MedicalSurgicalMedicalSurgical
Heartburn:
28 (26.4)65 (58.6)46 (34.8)77 (58.8)0
64 (60.4)38 (34.2)64 (48.5)44 (33.6)1–3
14 (13.2)8 (7.2)22 (16.7)10 (7.6)>3
Regurgitation:
71 (63.4)89 (75.4)83 (61.9)102 (77.3)0
37 (33.0)26 (22.0)47 (35.1)27 (20.5)1–3
4 (3.6)3 (2.5)4 (3.0)3 (2.3)>3
Difficulty swallowing:
82 (74.5)91 (77.1)102 (76.1)100 (75.8)0
25 (22.7)25 (21.2)27 (20.1)30 (22.7)1–3
3 (2.7)2 (1.7)5 (3.7)2 (1.5)>3
Wind from bowel:
14 (12.7)14 (11.9)20 (15.0)19 (14.4)0
30 (27.3)27 (22.9)35 (26.3)37 (28.0)1–3
66 (60.0)77 (65.3)78 (58.6)76 (57.6)>3
Belching:
27 (24.5)46 (39.3)33 (24.8)53 (40.2)0
37 (33.6)40 (34.2)48 (36.1)39 (29.5)1–3
46 (41.8)31 (26.5)52 (39.1)40 (30.3)>3
Nausea but unable to be sick:
92 (82.9)101 (85.6)110 (83.3)116 (87.9)0
16 (14.4)15 (12.7)17 (12.9)15 (11.4)1–3
3 (2.7)2 (1.7)5 (3.8)1 (0.8)>3
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f1908 doi: 10.1136/bmj.f1908 (Published 18 April 2013) Page 8 of 11
RESEARCH
Table 4| Differences at five year follow-up in self reported outcomes between participants randomised to surgery and those randomised
to medical management for chronic gastro-oesophageal reflux disease
Adjusted for treatment receivedIntention to treat
P valueMean difference (95% CI)*P valueMean difference (95% CI)*
0.00511.6 (3.5 to 19.8)0.0018.3 (3.2 to 13.4)REFLUX total score†
REFLUX symptom scores:
<0.00115.59 (7.52 to 23.66)<0.00111.82 (6.50 to 17.14)General discomfort
0.243‡5.12 (−3.50 to 13.73)0.218‡3.34 (−1.98 to 8.66)Wind and frequency
0.0077.32 (2.04 to 12.60)0.0054.97 (1.53 to 8.41)Nausea and vomiting
0.0108.27 (2.03 to 14.52)0.0035.97 (2.03 to 9.91)Activity limitation
0.282‡4.11 (−3.40 to 11.62)0.281‡2.54 (−2.09 to 7.18)Constipation and swallowing
SF-36 scores (norm based):
0.074‡3.35 (−0.33 to 7.03)0.082‡2.01 (−0.26 to 4.28)Physical functioning
0.606‡1.14 (−3.20 to 5.47)0.674‡0.57 (−2.10 to 3.24)Role physical
0.406‡1.65 (−2.25 to 5.54)0.218‡1.52 (−0.90 to 3.94)Bodily pain
0.068‡3.79 (−0.29 to 7.88)0.0342.76 (0.21 to 5.31)General health
0.928‡0.19 (−4.03 to 4.41)0.777‡0.37 (−2.23 to 2.98)Vitality
0.301‡2.36 (−2.13 to 6.84)0.221‡1.72 (−1.05 to 4.49)Social functioning
0.0344.56 (0.34 to 8.79)0.0442.67 (0.07 to 5.27)Role emotional
0.849‡0.40 (−3.72 to 4.51)0.650‡0.59 (−1.96 to 3.14)Mental health
0.168‡0.069 (−0.029 to 0.167)0.126‡0.047 (−0.013 to 0.108)EQ-5D score
*Difference is surgery group minus medical group. Analyses adjusted for body mass index, age, sex, baseline score, and baseline-group interaction unless stated
otherwise.
†REFLUX questionnaire a disease-specific measure of quality of life (score range 0–100).
‡Adjusted for body mass index, age, sex, and baseline score.
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Figures
Fig 1 Consort diagram of flow of participants through study
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Fig 2 Use of any antireflux drugs at baseline and at follow-up among participants with chronic gastro-oesophageal reflux
disease who were randomised to or selected surgical or medical treatment
Fig 3 Mean REFLUX questionnaire score at baseline and at follow-up points among participants with chronic
gastro-oesophageal reflux disease who were randomised to or selected surgical or medical treatment. Scores range 0–100,
the higher the score the better the participant felt
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